US4131971040 - Common Stock
HARMONY BIOSCIENCES HOLDINGS
NASDAQ:HRMY (4/24/2024, 4:20:01 PM)
After market: 29.23 0 (0%)29.23
+0.38 (+1.32%)
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 200 full-time employees. The company went IPO on 2020-08-19. The firm is focused on developing and commercializing therapies for patients living with rare neurological diseases, as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a molecule with a mechanism of action (MOA) specifically designed to increase histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a major wake-promoting neurotransmitter. The firm also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. Its product candidates also include Zygel, which is a synthetic cannabidiol.
HARMONY BIOSCIENCES HOLDINGS
630 W Germantown Pike, Suite 215
Plymouth Meeting PENNSYLVANIA 19462
P: 14845399800
CEO: John C. Jacobs
Employees: 200
Website: https://www.harmonybiosciences.com/
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April...
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and...
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to...
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the...
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming...
Here you can normally see the latest stock twits on HRMY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: